GLP-1 medications for weight loss: what the captain got right and wrong
Quick answer
The weight loss figures cited for liraglutide (~8%), semaglutide (~15%), and tirzepatide (~20%) align with peak results reported in the SCALE, STEP 1, and SURMOUNT-1 phase 3 trials respectively, but these reflect maximum-dose outcomes under controlled conditions and not average real-world results. The claim that tirzepatide carries fewer side effects than semaglutide is not supported by head-to-head trial data, as both drugs produce similar GI adverse event profiles during titration. Compounded versions of these medications are not FDA-approved and should not be assumed equivalent to brand-name formulations in terms of safety, potency, or efficacy review.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @realdrbae actually say?
The creator ran through all three major GLP-1 options and attached a specific average weight loss figure to each. Liraglutide (Victoza/Saxenda): about 8% body weight loss. Semaglutide (Ozempic/Wegovy): about 15%. Tirzepatide (Zepbound/Mounjaro): about 20%. They also said tirzepatide has "fewer side effects" than the others, and closed with an endorsement of compounded versions of these drugs as cheaper and "easier to get."
The dosing frequency claim in the caption is accurate: liraglutide is a daily injection, while semaglutide and tirzepatide are weekly. That part is not in dispute.
Does the science back up the weight loss figures?
Largely yes, with some important caveats. The 8%, 15%, and 20% figures are in the right ballpark for the highest-dose trials, but real-world averages skew lower. These numbers come from controlled clinical trials under ideal conditions, not typical patient outcomes.
For liraglutide 3.0 mg (Saxenda), the SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) found about 8% mean weight loss over 56 weeks versus placebo. That tracks. For semaglutide 2.4 mg (Wegovy), the STEP 1 trial (Wilding et al., 2021, NEJM) reported approximately 14.9% mean body weight reduction, so "about 15%" is a fair representation. For tirzepatide 15 mg (Zepbound), the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 20.9% at the maximum dose. The creator's figures reflect trial peaks, which is a meaningful distinction to flag.
What did they get wrong, and what did they get right?
The weight loss numbers are defensible when sourced to their respective phase 3 trials, so credit where it's due. But the claim that tirzepatide has "fewer side effects" is where things get shaky.
Both semaglutide and tirzepatide share a very similar GI side effect profile: nausea, vomiting, diarrhea, and constipation. SURMOUNT-1 reported nausea in roughly 30% of tirzepatide patients. The STEP trials showed comparable rates for semaglutide. There is no head-to-head trial as of mid-2025 that conclusively shows tirzepatide has a meaningfully lower side effect burden. Saying it has "fewer side effects" without qualification is an overstatement that could influence patient expectations in a misleading direction.
The compounded medication endorsement is also worth scrutinizing. The FDA considers compounded semaglutide and tirzepatide copies of brand-name drugs, not equivalents. Compounded versions are not FDA-approved, have not undergone the same efficacy and safety review, and their quality can vary by pharmacy. Framing them as simply "less expensive" without noting those distinctions is incomplete at best.
What should you actually know?
These percentages represent averages from controlled trials at maximum doses. In practice, many patients lose less. Adherence, dose titration, diet, and individual biology all affect outcomes significantly.
On the side effects question, the honest answer is that all three drugs cause GI symptoms, particularly during dose escalation. Tirzepatide's dual GIP/GLP-1 mechanism is different from semaglutide's single-receptor action, but that does not automatically mean a better tolerability profile for every patient. Your prescriber should walk through your personal medical history before selecting a medication.
Regarding compounded GLP-1 drugs: the FDA placed both semaglutide and tirzepatide on its shortage list, which temporarily permitted compounding. As shortage designations change, the legal and regulatory status of compounded versions shifts with them. A lower price does not guarantee equivalent quality, potency, or sterility standards. That context matters and was absent from this video.
Bottom line: should you trust this video?
The core weight loss claims are reasonably grounded in published trial data, which is more than you can say for a lot of GLP-1 content on TikTok. But the "fewer side effects" framing for tirzepatide lacks evidentiary support, and the compounded medication endorsement glosses over real regulatory and quality concerns. Treat the percentages as rough benchmarks, not guarantees, and talk to a licensed prescriber about which option actually fits your health profile and coverage situation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 medications for weight loss: what the captain got right and wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The weight loss figures cited for liraglutide (~8%), semaglutide (~15%), and tirzepatide (~20%) align with peak results reported in the SCALE, STEP 1, and SURMOUNT-1 phase 3 trials respectively, but these reflect maximum-dose outcomes under controlled conditions and not average real-world results.
FormBlends verdict
The weight loss figures cited for liraglutide (~8%), semaglutide (~15%), and tirzepatide (~20%) align with peak results reported in the SCALE, STEP 1, and SURMOUNT-1 phase 3 trials respectively, but these reflect maximum-dose outcomes under controlled conditions and not average real-world results. The claim that tirzepatide carries fewer side effects than semaglutide is not supported by head-to-head trial data, as both drugs produce similar GI adverse event profiles during titration. Compounded versions of these medications are not FDA-approved and should not be assumed equivalent to brand-name formulations in terms of safety, potency, or efficacy review.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The weight loss figures cited for liraglutide (~8%), semaglutide (~15%), and tirzepatide (~20%) align with peak results reported in the SCALE, STEP 1, and SURMOUNT-1 phase 3 trials respectively, but these reflect maximum-dose outcomes under controlled conditions and not average real-world results. The claim that tirzepatide carries fewer side effects than semaglutide is not supported by head-to-head trial data, as both drugs produce similar GI adverse event profiles during titration. Compounded versions of these medications are not FDA-approved and should not be assumed equivalent to brand-name formulations in terms of safety, potency, or efficacy review.
- The SCALE trial (Pi-Sunyer et al., 2015, NEJM) reported 8% average weight loss with liraglutide 3.0 mg at 56 weeks, supporting the creator's figure.
- STEP 1 (Wilding et al., 2021, NEJM) showed 14.9% mean weight loss with semaglutide 2.4 mg weekly, making the '~15%' claim accurate for trial conditions.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The SCALE trial (Pi-Sunyer et al., 2015, NEJM) reported 8% average weight loss with liraglutide 3.0 mg at 56 weeks, supporting the creator's figure.
- STEP 1 (Wilding et al., 2021, NEJM) showed 14.9% mean weight loss with semaglutide 2.4 mg weekly, making the '~15%' claim accurate for trial conditions.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found up to 20.9% weight loss at tirzepatide 15 mg, but this is a maximum-dose trial result, not a guaranteed outcome.
- No head-to-head RCT confirms that tirzepatide has fewer side effects than semaglutide; both drugs produce GI symptoms in roughly 25-30% of patients during titration.
- Compounded GLP-1 medications are not FDA-approved and are not considered equivalent to brand-name drugs in terms of regulatory review, potency verification, or sterility standards.
- Real-world weight loss outcomes consistently fall below clinical trial averages due to dose titration, adherence, and individual variation.
- Insurance coverage and formulary access are legitimate factors in drug selection, but the decision should be made with a licensed prescriber, not based on social media recommendations alone.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Jonathan Kaplan · TikTok creator
925.4K views on this video
@amy 👏 Here’s a break down of all the available GLP-1 medications for weight loss. To review: Liraglutide is taken daily while Semaglutide and Tirzepatide can be taken weekly.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Jonathan Kaplan, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.